Baird raised the firm’s price target on Medpace (MEDP) to $354 from $349 and keeps a Neutral rating on the shares. The firm said the sector chop, political headlines galore, and presently weak biotech funding each keep them more guarded than normal. Yet this is exactly the type of company that long-term investors should crave and the firm has a very positive long-term bias on the shares.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Snap upgraded, McDonald’s downgraded: Wall Street’s top analyst calls
- Medpace price target lowered to $372 from $413 at TD Cowen
- Medpace downgraded to Neutral from Outperform at Baird
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- Medpace reports Q3 EPS $3.01, consensus $2.78